



Kesimpta in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

NEUROLOGY · RELAPSING MULTIPLE SCLEROSIS

The clinical situation

Kesimpta (ofatumumab) is a subcutaneous anti-CD20 monoclonal antibody FDA-approved for relapsing forms of multiple sclerosis, designed for home self-administration. Manufactured by Novartis. Standard regimen is 20 mg SC weekly for the first three weeks, then 20 mg SC monthly. Pre-treatment workup covers hepatitis B screening, vaccination review (including live vaccines before depletion), immunoglobulins, and baseline infection screen per FDA labelling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your neurologist documents MS subtype, MRI review, prior DMTs, and Kesimpta rationale.
- 2 Baseline screening.** Hepatitis B, immunoglobulins, vaccination review/update, and baseline infection screen per FDA labelling.
- 3 SFDA named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, dosing calendar, and chain-of-custody commitment.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with validated 2–8°C shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases product against the prescription; patient training for at-home self-administration proceeds per protocol.

Indicative economics

Reference US cash-pay range: USD 90,000–110,000 per year of Kesimpta (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete SFDA application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Novartis authorised distribution.

Documentation. Physician kit tailored to SFDA review, with anti-CD20 class safety annex. **Logistics.** Validated cold-chain internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through monthly self-administration. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Kesimpta × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/kesimpta-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team